Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ).
JCR Pharmaceuticals, a Japan-based specialty drug maker focused on rare diseases and advanced biologic therapies, is leveraging its proprietary technologies and expanding its footprint across major global markets including the U.S. and Europe. Its commercial and pipeline assets are concentrated in treatments for growth disorders, lysosomal storage disorders and other severe conditions with high unmet medical need.
The company announced it has partially corrected its previously disclosed consolidated financial results for the nine months ended December 31, 2025, after identifying errors in the original filing. The revisions, which include changes to certain numerical data to be re-submitted, may affect how investors interpret recent performance and forecasts, underscoring the importance of accurate disclosure as JCR pursues growth in rare disease therapeutics and maintains engagement with institutional investors and analysts.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen900.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company focused on developing next-generation therapies, particularly for rare diseases and complex healthcare challenges. With a 50-year legacy in Japan and an expanding presence in the U.S., Europe, and Latin America, its portfolio includes approved treatments for growth disorders, lysosomal storage diseases such as MPS II and Fabry disease, acute graft-versus-host disease, and renal anemia, along with a pipeline targeting multiple mucopolysaccharidoses worldwide.
Average Trading Volume: 551,901
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen69.05B
For a thorough assessment of 4552 stock, go to TipRanks’ Stock Analysis page.